文献速递流行病学与生物统计临床试验与 GCP

儿童和青少年焦虑筛查:美国预防服务工作组证据报告与系统综述

Screening for Anxiety in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2022-01-01

本系统综述纳入39项研究(N=6065),评估儿童青少年焦虑筛查工具的准确性及治疗获益与危害。筛查工具灵敏度0.34-1.00、特异度0.47-0.99;认知行为疗法和药物治疗与获益相关,未报告与危害有统计学显著关联。

要点

  • 筛查工具灵敏度0.34-1.00、特异度0.47-0.99,部分工具准确性尚可。
  • 认知行为疗法与症状改善、应答、缓解及诊断丧失相关。
  • 药物治疗与症状改善和应答相关,但与功能改善关系不一。

核心结论

  • 间接证据提示部分筛查工具具有合理的准确性。
  • 认知行为疗法和药物治疗与获益相关,未报告与危害有统计学显著关联。

研究设计与样本

  • 系统综述纳入39项研究(N=6065),检索PubMed、Cochrane Library、PsycINFO、CINAHL及试验注册库至2021年7月19日,并追溯参考文献、专家及监测至2022年6月1日。
  • 纳入英文随机临床试验、诊断准确性研究、认知行为疗法或美国食品药品监督管理局批准药物的随机临床试验,以及报告危害的随机临床试验、观察性研究和系统综述。
  • 由两名评价者评估标题、摘要、全文及研究质量并提取数据,当至少3项相似研究时进行Meta分析。

主要发现

  • 10项研究(n=3260)报告筛查工具灵敏度范围为0.34至1.00,特异度范围为0.47至0.99。
  • 29项随机临床试验(n=2805)报告治疗:22项认知行为疗法、6项药物治疗、1项认知行为疗法联合舍曲林及认知行为疗法加舍曲林。
  • 与常规照护或等待名单对照相比,认知行为疗法在症状改善(变化幅度因结局指标而异)、应答(合并相对风险RR=1.89,95%CI 1.17至3.05;n=606;6项研究)、缓解(RR=2.68,95%CI 1.48至4.88;n=321;4项研究)及诊断丧失(RR范围3.02-3.09)方面相关。
  • 与安慰剂相比,药物治疗在2项合并症状改善指标上相关:儿童焦虑评定量表均数差-4.0(95%CI -5.5至-2.5;n=726;5项研究)和临床总体印象-严重程度量表均数差-0.84(95%CI -1.13至-0.55;n=550;4项研究),以及应答(RR=2.11,95%CI 1.58至2.98;n=370;5项研究)。
  • 11项随机临床试验(n=1293)报告焦虑治疗的危害,自杀相关危害罕见,差异无统计学显著。

关键数值与推荐

  • 筛查工具灵敏度0.34-1.00,特异度0.47-0.99(10项研究,n=3260)。
  • 认知行为疗法 vs 常规照护或等待名单:应答RR=1.89(95%CI 1.17至3.05;n=606;6项研究)。
  • 认知行为疗法 vs 常规照护或等待名单:缓解RR=2.68(95%CI 1.48至4.88;n=321;4项研究)。
  • 药物治疗 vs 安慰剂:儿童焦虑评定量表均数差-4.0(95%CI -5.5至-2.5;n=726;5项研究)。
  • 药物治疗 vs 安慰剂:临床总体印象-严重程度量表均数差-0.84(95%CI -1.13至-0.55;n=550;4项研究)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Anxiety in children and adolescents is associated with impaired functioning, educational underachievement, and future mental health conditions. OBJECTIVE: To review the evidence on screening for anxiety in children and adolescents to inform the US Preventive Services Task Force. DATA SOURCES: PubMed, Cochrane Library, PsycINFO, CINAHL, and trial registries through July 19, 2021; references, experts, and surveillance through June 1, 2022. STUDY SELECTION: English-language, randomized clinical trials (RCTs) of screening; diagnostic test accuracy studies; RCTs of cognitive behavioral therapy (CBT) or US Food and Drug Administration-approved pharmacotherapy; RCTs, observational studies, and systematic reviews reporting harms. DATA EXTRACTION AND SYNTHESIS: Two reviewers assessed titles/abstracts, full-text articles, and study quality and extracted data; when at least 3 similar studies were available, meta-analyses were conducted. MAIN OUTCOMES AND MEASURES: Test accuracy, symptoms, response, remission, loss of diagnosis, all-cause mortality, functioning, suicide-related symptoms or events, adverse events. RESULTS: Thirty-nine studies (N = 6065) were included. No study reported on the direct benefits or harms of screening on health outcomes. Ten studies (n = 3260) reported the sensitivity of screening instruments, ranging from 0.34 to 1.00, with specificity ranging from 0.47 to 0.99. Twenty-nine RCTs (n = 2805) reported on treatment: 22 on CBT, 6 on pharmacotherapy, and 1 on CBT, sertraline, and CBT plus sertraline. CBT was associated with gains on several pooled measures of symptom improvement (magnitude of change varied by outcome measure), response (pooled relative risk [RR], 1.89 [95% CI, 1.17 to 3.05]; n = 606; 6 studies), remission (RR, 2.68 [95% CI, 1.48 to 4.88]; n = 321; 4 studies), and loss of diagnosis (RR range, 3.02-3.09) when compared with usual care or wait-list controls. The evidence on functioning for CBT was mixed. Pharmacotherapy, when compared with placebo, was associated with gains on 2 pooled measures of symptom improvement-mean difference (Pediatric Anxiety Rating Scale mean difference, -4.0 [95% CI, -5.5 to -2.5]; n = 726; 5 studies; and Clinical Global Impression-Severity scale mean difference, -0.84 [95% CI, -1.13 to -0.55]; n = 550; 4 studies) and response (RR, 2.11 [95% CI, 1.58 to 2.98]; n = 370; 5 studies)-but was mixed on measures of functioning. Eleven RCTs (n = 1293) reported harms of anxiety treatments. Suicide-related harms were rare, and the differences were not statistically significantly different. CONCLUSIONS AND RELEVANCE: Indirect evidence suggested that some screening instruments were reasonably accurate. CBT and pharmacotherapy were associated with benefits; no statistically significant association with harms was reported.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Viswanathan M, Wallace IF, Cook Middleton J, et al. Screening for Anxiety in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022. PMID: 36219404. doi:10.1001/jama.2022.16303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。